M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor(IC50 :54nM;Ki:4.33 nM).M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral acti
Relzomostat is a MetAP2 inhibitor, specifically targeting methionine aminopeptidase 2. It holds potential in research concerning obesity, type 2 diabetes, and other conditions associated with obesity.
Aclimostat (ZGN-1061) is a highly potent inhibitor of the MetAP2 enzyme that demonstrates promising efficacy and safety profiles in preclinical trials. In a mouse model of obesity and insulin resistance, ZGN-1061 exhibits comparable weight loss efficacy to beloranib, while also improving metabolic parameters. Additionally, ZGN-1061 induces consistent changes in gene transcription in HepG2 cells, further supporting its positive pharmacological effects.
A-849519 is a reversible inhibitor of MetAP2 that has demonstrated anti-angiogenesis and anticancer activity in a number of in vitro and in vivo models. In this study, we evaluated the anticancer activity of A-849519 in a modified Dunning model of androgen-independent prostate cancer and compared its efficacy with TNP-470, an established MetAP2 inhibitor.
PPI-2458 is a synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class.
A-357300 is a potent, selective, reversible MetAP2 inhibitor with IC50 of 0.12 uM. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.